NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 133)
Posted On: 12/20/2018 4:19:00 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Cut Costs with In-House R&D Laboratory
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently submitted a Health Canada research application for a license that will permit in-house research in its new Kelowna-based research and development (“R&D”) laboratory. Construction of the new lab, which will be located within Lexaria’s new head office, is anticipated to be completed by the end of January 2019. A recent article further discussing LXRP reads, “Having the work done in-house will help expand the work schedule and reduce costs and development timelines. The company is currently recruiting new staff as it prepares for an increase in operations. Once the research license has been approved under Health Canada’s Cannabis Tracking and Licensing System, Lexaria expects to begin work on cannabinoid-related formulations. There are also plans in place to begin experimental work on nicotine formulations, nonsteroidal anti-inflammatory drugs, vitamins and other bioactive compounds.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently submitted a Health Canada research application for a license that will permit in-house research in its new Kelowna-based research and development (“R&D”) laboratory. Construction of the new lab, which will be located within Lexaria’s new head office, is anticipated to be completed by the end of January 2019. A recent article further discussing LXRP reads, “Having the work done in-house will help expand the work schedule and reduce costs and development timelines. The company is currently recruiting new staff as it prepares for an increase in operations. Once the research license has been approved under Health Canada’s Cannabis Tracking and Licensing System, Lexaria expects to begin work on cannabinoid-related formulations. There are also plans in place to begin experimental work on nicotine formulations, nonsteroidal anti-inflammatory drugs, vitamins and other bioactive compounds.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼